AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 10 years ago, it would be worth $3,991.28 today based on a price of $224.50 for ABBV at the time of writing.

Wondering if AbbVie is still a smart buy after its huge run, or if the value has already been squeezed out of the stock? Let ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $250.0 for AbbVie, spanning the last three months.

TheFly reported on December 15 that Bank of America (BofA) lowered its price target for ABBV to $233 from $248 while maintaining a Neutral rating, reflecting a modestly reduced valuation outlook even ...

The U.S. pharmaceutical industry in 2025 remains one of the nation’s most dynamic and profitable economic sectors.

Evolus faces competitive pressures and cash challenges despite growth. Read about what this means for investors and the 2026 ...

Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield.

AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald ...

Launched on October 20, 2011, the Schwab U.S. Dividend Equity ETF (SCHD) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US ...

Explore eight major immunology and inflammation (I&I) partnerships in 2025, from early-stage research to late-stage licensing ...

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...